Healthcare.gov contractor changes hands

After the debacle of the healthcare.gov rollout last fall, it’s hardly surprising that the problems would lead to changes. The Centers for Medicare & Medicaid Services will not renew its contract with CGI when it expires Feb. 28 and instead bring Accenture Federal Services on board.

Accenture is getting $45 million to handle the “initial phase of the project,” according to a release, which includes drafting a transition plan to determine the work needed to make effective fixes to the portal. That roadmap will define the value of the 12-month contract.

Dozens of firms have been involved in building healthcare.gov but CGI has gotten the bulk of the blame for the website’s poor performance.

Accenture is one of the world’s largest consulting firms, and has built sites for the Internal Revenue Service, U.S. Census Bureau and the U.S. Department of Education. The firm also built California’s new health insurance exchange, which has worked relatively well since its October launch. Until now, Accenture hasn’t had significant input on the healthcare.gov portal.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.